Hiasa Masahiro, Harada Takeshi, Tanaka Eiji, Abe Masahiro
Department of Orthodontics and Dentofacial Orthopedics, Tokushima University, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Jpn Dent Sci Rev. 2021 Nov;57:164-173. doi: 10.1016/j.jdsr.2021.08.006. Epub 2021 Sep 23.
Multiple myeloma (Plasma cell myeloma), a malignancy of the plasma cells, exhibits tumor expansion preferentially in the bone marrow and the development of bone-destructive lesions. Multiple myeloma is still an incurable disease with changes in the bone marrow microenvironment in favor of the survival and proliferation of multiple myeloma cells and bone destruction. In this review, we described the recent findings on the regulators involved in the development of myeloma bone diseases, and succinctly summarize currently available therapeutic options and the development of novel bone modifying agents for myeloma treatment.
多发性骨髓瘤(浆细胞骨髓瘤)是一种浆细胞恶性肿瘤,优先在骨髓中表现出肿瘤扩张并形成骨破坏病变。多发性骨髓瘤仍然是一种无法治愈的疾病,其骨髓微环境发生变化,有利于多发性骨髓瘤细胞的存活、增殖及骨破坏。在本综述中,我们描述了骨髓瘤骨病发生过程中相关调节因子的最新研究发现,并简要总结了目前可用的治疗选择以及用于骨髓瘤治疗的新型骨修饰剂的研发情况。